AstraZeneca has suffered a setback after its investigational oncology agent Recentin failed in a second late-stage trial for colorectal cancer.

The Anglo-Swedish drugmaker has announced the top-line results this morning of a Phase III study evaluating Recentin (cediranib) for the first-line treatment of metastatic colorectal cancer. The drug met the co-primary endpoint of the Horizon II study, namely improving progression-free survival, but showed no improvement in overall survival.

A couple of months ago, Recentin failed in another mCRC tstudy, Horizon III, which was a head-to-head trial with Roche’s blockbuster Avastin (bevacizumab) plus chemotherapy. As a result of these two trials, AstraZeneca says it does not intend to file regulatory submissions in first-line mCRC.

This is not the end of the road for Recentin, however, as the results of a Phase III study evaluating the drug for the treatment of recurrent glioblastoma are expected soon. The company added that it “currently examining whether cediranib may have applications in a number of different tumour types”.

Complete data from the two Horizon trials will be submitted to a forthcoming medical congress, AstraZeneca added.